Oversubscribed Series B to fund a Phase 2b trial of Zabalafin Hydrogel in atopic dermatitis and a Phase 2 program in molluscum contagiosum.
- Amount
- $25M
- Stage
- Series B
- Announced
- 12 December 2025
- Lead
- QCA Investment Group
- Other investors
- Angel Physicians Fund, Serial Stage Venture Partners
- Use of funds
- Oversubscribed Series B to fund a Phase 2b trial of Zabalafin Hydrogel in atopic dermatitis and a Phase 2 program in molluscum contagiosum.
- Checked
- Announced by the company